core laboratories - CLB

CLB

Close Chg Chg %
12.49 0.04 0.32%

Open Market

12.53

+0.04 (0.32%)

Volume: 112.53K

Last Updated:

Sep 9, 2026, 11:03 AM EDT

Company Overview: core laboratories - CLB

CLB Key Data

Open

$12.76

Day Range

12.53 - 12.76

52 Week Range

9.80 - 20.31

Market Cap

$575.39M

Shares Outstanding

45.88M

Public Float

45.21M

Beta

1.08

Rev. Per Employee

N/A

P/E Ratio

21.86

EPS

$0.57

Yield

32.08%

Dividend

$0.01

EX-DIVIDEND DATE

Aug 10, 2026

SHORT INTEREST

N/A

AVERAGE VOLUME

482.47K

 

CLB Performance

1 Week
 
-0.56%
 
1 Month
 
9.87%
 
3 Months
 
-5.24%
 
1 Year
 
0.73%
 
5 Years
 
-55.18%
 

CLB Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 4
Full Ratings ➔

About core laboratories - CLB

Core Laboratories, Inc. provides proprietary and patented reservoir description and production enhancement services. It operates through the Reservoir Description and Production Enhancement segments. The Reservoir Description segment engages in petroleum reservoir analysis for energy. The Production Enhancement segment includes services and manufactured products associated with reservoir well completions, perforations, stimulation, production and well abandonment. The company was founded in 1936 and is headquartered in Houston, TX.

CLB At a Glance

Core Laboratories, Inc.
6316 Windfern Road
Houston, Texas 77040
Phone 1-713-328-2673 Revenue 526.52M
Industry Oil & Gas Production Net Income 29.67M
Sector Energy Minerals 2025 Sales Growth 0.51%
Fiscal Year-end 12 / 2026 Employees 3,300
View SEC Filings

CLB Valuation

P/E Current 21.858
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 25.086
Price to Sales Ratio 1.432
Price to Book Ratio 2.778
Price to Cash Flow Ratio 20.36
Enterprise Value to EBITDA 14.195
Enterprise Value to Sales 1.712
Total Debt to Enterprise Value 0.182

CLB Efficiency

Revenue/Employee 159,551.515
Income Per Employee 8,990.606
Receivables Turnover 4.359
Total Asset Turnover 0.897

CLB Liquidity

Current Ratio 2.025
Quick Ratio 1.511
Cash Ratio 0.214

CLB Profitability

Gross Margin 17.907
Operating Margin 9.279
Pretax Margin 8.841
Net Margin 5.635
Return on Assets 5.053
Return on Equity 11.456
Return on Total Capital 6.90
Return on Invested Capital 7.064

CLB Capital Structure

Total Debt to Total Equity 61.665
Total Debt to Total Capital 38.144
Total Debt to Total Assets 28.085
Long-Term Debt to Equity 57.358
Long-Term Debt to Total Capital 35.48
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Core Laboratories - CLB

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
489.74M 509.79M 523.85M 526.52M
Sales Growth
+4.14% +4.10% +2.76% +0.51%
Cost of Goods Sold (COGS) incl D&A
410.82M 415.74M 435.48M 432.24M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
17.16M 15.78M 14.95M 14.65M
Depreciation
16.48M 15.29M 14.45M 14.29M
Amortization of Intangibles
685.00K 490.00K 504.00K 359.00K
COGS Growth
+6.32% +1.20% +4.75% -0.74%
Gross Income
78.92M 94.05M 88.37M 94.28M
Gross Income Growth
-5.87% +19.17% -6.04% +6.69%
Gross Profit Margin
+16.11% +18.45% +16.87% +17.91%
2022 2023 2024 2025 5-year trend
SG&A Expense
38.12M 40.26M 39.77M 45.43M
Research & Development
- - - -
-
Other SG&A
38.12M 40.26M 39.77M 45.43M
SGA Growth
-13.71% +5.62% -1.21% +14.23%
Other Operating Expense
- - - -
-
Unusual Expense
(669.00K) 1.69M (6.62M) (7.59M)
EBIT after Unusual Expense
41.47M 52.10M 55.23M 56.44M
Non Operating Income/Expense
(241.00K) 2.14M 3.09M 679.00K
Non-Operating Interest Income
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
11.57M 13.43M 12.37M 10.57M
Interest Expense Growth
+26.42% +16.08% -7.90% -14.53%
Gross Interest Expense
11.57M 13.43M 12.37M 10.57M
Interest Capitalized
- - - -
-
Pretax Income
29.66M 40.82M 45.95M 46.55M
Pretax Income Growth
-17.72% +37.61% +12.58% +1.30%
Pretax Margin
+6.06% +8.01% +8.77% +8.84%
Income Tax
10.30M 4.19M 14.03M 15.51M
Income Tax - Current - Domestic
10.95M 15.25M 13.41M 14.11M
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
(657.00K) (11.06M) 620.00K 1.40M
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
19.66M 37.03M 32.15M 30.39M
Minority Interest Expense
205.00K 350.00K 753.00K 722.00K
Net Income
19.45M 36.68M 31.40M 29.67M
Net Income Growth
-1.39% +88.53% -14.38% -5.51%
Net Margin Growth
+3.97% +7.19% +5.99% +5.63%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
19.45M 36.68M 31.40M 29.67M
Preferred Dividends
- - - -
-
Net Income Available to Common
19.45M 36.68M 31.40M 29.67M
EPS (Basic)
0.4198 0.7856 0.6695 0.639
EPS (Basic) Growth
-2.10% +87.14% -14.78% -4.56%
Basic Shares Outstanding
46.33M 46.68M 46.90M 46.43M
EPS (Diluted)
0.4155 0.7717 0.6585 0.6309
EPS (Diluted) Growth
-1.66% +85.73% -14.67% -4.19%
Diluted Shares Outstanding
46.81M 47.52M 47.69M 47.03M
EBITDA
57.96M 69.57M 63.56M 63.50M
EBITDA Growth
-0.38% +20.03% -8.65% -0.08%
EBITDA Margin
+11.84% +13.65% +12.13% +12.06%

Snapshot

Average Recommendation HOLD Average Target Price 15.50
Number of Ratings 4 Current Quarters Estimate 0.154
FY Report Date 09 / 2026 Current Year's Estimate 0.456
Last Quarter’s Earnings 0.11 Median PE on CY Estimate N/A
Year Ago Earnings 0.75 Next Fiscal Year Estimate 0.735
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 4 4 4 4
Mean Estimate 0.15 0.16 0.46 0.74
High Estimates 0.16 0.18 0.51 0.83
Low Estimate 0.15 0.13 0.37 0.58
Coefficient of Variance 3.32 14.83 13.57 14.96

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 2 2 1
OVERWEIGHT 0 0 0
HOLD 0 0 1
UNDERWEIGHT 1 1 1
SELL 1 1 1
MEAN Hold Hold Hold

Core Laboratories in the News